Thomas Carell hält Vortrag beim Novo Nordisk Symposium „Frontiers in Biophysics and Chemical Biology“
Continue readingThomas Carell beim Novo Nordisk Symposium „Frontiers in Biophysics and Chemical Biology“ in Cambridge
LMU spin-off RNhale GmbH receives millions in funding
LMU spin-off RNhale GmbH receives millions in funding
20. March 2025
The RNhale GmbH, an LMU spin-off, has received 2.5 million euros in funding from the European Innovation Council (EIC). The company will use the funds to further work on the realization of a drug for the treatment of asthma.
Epicure wins the Science4Life Venture Cup
Epicure wins the Science4Life Venture Cup
19. March 2025
Das Startup Epicure wurde bei den Academy Days von Science4Life als eines von 5 Startups mit dem Science4Life Venture Cup ausgezeichnet.
LMU spin-off QuGen GmbH founded!
LMU spin-off QuGen GmbH founded!
18. September 2023
QuGen GmbH, founded by Thomas carell and Pascal Giehr, provides high-sensitive long read sequencing (PacBio), bisulfite-free sequencing of DNA methylation and mass spectrometry quantification of non-canonical nucleobases in DNA and RNA. This includes also sample preparation and data analysis. With this QuGen fulfills unmet needs in quantification and positional information of epigenetic nucleobases.
ERC Starting Grant for Dr. Daniel Andergassen
ERC Starting Grant for Dr. Daniel Andergassen
November 2023
Dr Daniel Andergassen received an ERC Starting Grant for his research on the molecular causes of gender-specific differences in heart failure.
m4 Award for Prof. Urlike Protzer and her Project TherVacB
m4 Award for Prof. Urlike Protzer and her Project TherVacB
25. October 2023
Prof. Ulrike Protzer and her project TherVacB was one of the 5 winners of the Bavarian m4 Award from BioM. TherVacB is a project for the development of a therapeutic vaccine against Hepatitis B virus.
The m4 Award is a pre-funding award for innovative, high-potential medical biotechnology projects, with prize funds to further explore solutions to innovative medical problems.
ERC Starting Grant for Prof. Baer de Oliveira Mann
ERC Starting Grant for Prof. Baer de Oliveira Mann
September 2023
Prof Baer de Oliveira Mann received an ERC Starting Grant for her NTase Pro project.
CNATM begins work
CNATM begins work
On May 1, the Cluster for Nucleic Acid Therapeutics Munich (CNATM) started its work.
CNATM is an innovation network of science and industry, which is funded with five million euros annually by the federal government, the Free State of Bavaria and participating companies. The research network consists of scientists from the leading universities LMU and TUM. The universities of Regensburg and Würzburg, the Helmholtz Center Munich and 17 companies from the region around Munich are also involved. A total of 22 applications were awarded funding, marking the start of the Nucleic Acid Isar Valley.
The multilateral collaborations of CNATM are creating a network from which novel nucleic acid-based drugs and next-generation vaccines will be developed. Recent discoveries give rise to the hope that the ability to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many people. There is no substance class that is better suited to personalized medicine than nucleic acids. The Future Cluster wants to help nucleic acid therapies achieve a breakthrough and thus make a contribution that makes sense: curing people and creating jobs in and around Munich.
CNATM one of 7 future clusters in 2nd round in Germany
CNATM one of only 7 future clusters in Germany
We are very happy, to be one of only 7 clusters4future in Germany and the only one in Bavaria of the second round of the competition.
Our thanks go to all members and partner companies who made this possible.
Eisbach Bio GmbH among the 5 German biotech hopes
Eisbach Bio GmbH among the 5 German biotech hopes
The LMU spin-off Eisbach Bio GmbH was mentioned Handelsblatt as one of the top 5 promising biotech companies in Germany. They were mentioned particularly frequently by leading venture capitalists when it comes to promising projects in early research phases.
